A2 Lianidou: Cannot expect 100%, sometimes filtration required. Next paper - compares methods, more w/filtration systems in H&N SCC #AAC
8:47am April 15th 2018 via Hootsuite
Q: Ab-free tech- filtration systems stress cells to change profile? Lianidou: At times has to be done. Corr.w/EpCAM tech not 100% #AACR18
8:46am April 15th 2018 via Hootsuite
Q: Usefulness in clinical practice? Lianidou: Where we want to go, analysis is reliable, however widespread use potential is there. #AACR18
8:45am April 15th 2018 via Hootsuite
Lianidou: 'CTCs Dx not dependable clinically'. Acknowledges many collaborators, including Christine Alix-Panabieres, Klaus Pantel #AACR18
8:42am April 15th 2018 via Hootsuite
Lianidou: Concludes with comparison between ctDNA and CTCs - adv of CTCs includes miRNA, protein analysis; can ID mets #AACR18
Lianidou: Using dx leukopheresis. 2.3mL equiv to 60mL blood. #AACR18
8:40am April 15th 2018 via Hootsuite
Lianidou: https://t.co/GvkxCYCbZU is a huge project aiming to liquid biopsy clinical eval of robust assays. Same sample across labs? #AACR18
8:39am April 15th 2018 via Hootsuite
Lianidou: Many Q's - pre-analytical, what is the analytical validation, what is the clinical validation. Many groups working #AACR18
8:38am April 15th 2018 via Hootsuite
Lianidou: What about quality control? FDA of CellSearch dep on full control from beginning to end; reviews feas., anal validation... #AACR18
Lianidou: #AACR18 https://t.co/PCoVm1BuYk Lots of technology development; combining CTCs along with EV RNA-Seq
8:37am April 15th 2018 via Hootsuite
Lianidou: SCLC analysis from Dive's group '14 https://t.co/qYVCFQ3Jeo #AACR18
8:36am April 15th 2018 via Hootsuite
Lianidou: #AACR18 Microfluidic western blotting from sc (!) https://t.co/Aj0tf5jLUd
8:34am April 15th 2018 via Hootsuite
Lianidou: sc CNV from Silicon Biosystems '18 ref https://t.co/DW6IHS5MZV #AACR18
8:33am April 15th 2018 via Hootsuite
Lianidou: #AACR18 In '12 ref https://t.co/EVyCixcGM8 shows sc heterogeneity, diversity
8:31am April 15th 2018 via Hootsuite
Lianidou: Presenting four posters here - ESR1 methylation, sample storage for liquid biopsy. #AACR18 Moving toward sc analysis
8:30am April 15th 2018 via Hootsuite
Lianidou: #AACR18 Latest- CTCs from CellSearch cartridges, looked at ESR1 methylation status. Correl. to PFS, OS https://t.co/Mmoj9Nd507
8:29am April 15th 2018 via Hootsuite
Lianidou: For high risk PC - multiplex GEx '18 Clin Chem https://t.co/ZrBVhfGpCP #AACR18
8:28am April 15th 2018 via Hootsuite
Lianidou: Prognostic sig of PD-L1 in head and neck SCC '17 ref https://t.co/EVTSqdKY6X #AACR18
8:25am April 15th 2018 via Hootsuite
Lianidou: OS in early BC, dev multiplex RT-PCR '11 https://t.co/wUalyD22b0 no preampl to retain quant info #AACR18
8:24am April 15th 2018 via Hootsuite
Lianidou: Shows lab photo - all female - her work focuses on GEx '08 ref https://t.co/kGdqywnhC9 #AACR18
8:23am April 15th 2018 via Hootsuite
Lianidou: Ovarian - not many groups, GEx mainly. '17 ref https://t.co/Qt1TOuzE3N #AACR18
8:22am April 15th 2018 via Hootsuite
Lianidou: PD-1 and PD-L1 in NSCLC, shows nice images from '18 ref https://t.co/06rsFAHywt #AACR18
8:21am April 15th 2018 via Hootsuite
Lianidou: #AACR18 ALK copy number in CTCs related to prog-free surv in NSCLC https://t.co/H7WrijmITt
8:20am April 15th 2018 via Hootsuite
Lianidou: #AACR18 NSCLC: a 'tremendous amt of new knowledge'; EGFR '08, NOTCH-1 '16; PD-L1 in CTCs from LuCa.
8:19am April 15th 2018 via Hootsuite
Lianidou: #AACR18 '16 https://t.co/m3Z4U7bZrM combines CellSearch , an in vivo CellCollector, EPISPOT for non mPC
8:18am April 15th 2018 via Hootsuite
Lianidou: #AACR18 AR-V7's usefulness in mPC '17 ref https://t.co/cOCW8Wt9sj
8:16am April 15th 2018 via Hootsuite
Lianidou: For prostate cancer: metastatic castration resist prostate ca: CellSearch study. AR-V7 derived from CTC: for mPC #AACR18
8:15am April 15th 2018 via Hootsuite
Lianidou: OS worse and DFS worse w/CTC counts. Metanalysis (21 studies) show prognostic value. (in press) #AACR18
8:14am April 15th 2018 via Hootsuite
Lianidou: RNA based gene exp - AR, others genes; Rossi CCR '17 https://t.co/rAaSHWGrbP both ctDNA and CTC (CellSearch, Guardant) #AACR18
8:12am April 15th 2018 via Hootsuite
Lianidou: ESR1 mutations detected - '17 ref https://t.co/4zNg4znFKM impt for mBC #AACR18
8:10am April 15th 2018 via Hootsuite
Lianidou: Det of therapeutic targets - HER2, shown by Pantel and others. Software recent PLOS One https://t.co/Jtoukp5lwR to detect #AACR18
8:08am April 15th 2018 via Hootsuite
Lianidou: In Br ca - '04 NEJM https://t.co/kuwkU5pg3P 'seminal paper' for CellSearch, assoc'd with survival oin mBC #AACR18
8:07am April 15th 2018 via Hootsuite
Lianidou: #AACR18 EMT occurs in CTC Shows fig from '11 ref https://t.co/y22U6PDcus
8:05am April 15th 2018 via Hootsuite
Lianidou: #AACR18 Clin Chem '11 https://t.co/tZYtQNepLy EMT plays impt role in CTC isol and detection. EpCAM, CK on left, Vimentin on right
Lianidou: From size- or affinity-based, to physical characteristics. Imaging or molecular: complementary methods #AACR18
8:03am April 15th 2018 via Hootsuite
Lianidou: CTCs, ctDNA, and circ miRNAs. More than 100 years ago history; PNAS 1988 ref; many methods of selection #AACR18
8:02am April 15th 2018 via Hootsuite
Lianidou: Rapidly expanding liquid biopsy fld; addresses major needs like Dx, prognosis, detection of resid disease, risk of relapse #AACR18
8:00am April 15th 2018 via Hootsuite
Evi Lianidou (Athens GR) CTC characterization and applications #AACR18
7:59am April 15th 2018 via Hootsuite
@PeerView You are welcome - I enjoyed last night's presentation very much! Dale
7:59am April 15th 2018 via Hootsuite in reply to PeerView
Q: Diff pipelines give diff numbers? Riaz: Yes it has to be locked down, to get relative numbers correct #AACR18
9:36pm April 14th 2018 via Hootsuite
Peters: Neon, Gritstone, IVC (?) three companies pursuing personal neoAg Rx #AACR18
9:35pm April 14th 2018 via Hootsuite
Peters: '18 Science review https://t.co/uZYedZQlEn Synthetic peptides, synthetic RNA, all in comb w/I-O Rx #AACR18
9:33pm April 14th 2018 via Hootsuite
Peters: Vaccines based upon neoAg: clinical activity of vaccine '17 Nature https://t.co/R7RTHMkfsV 6 ptx w/20 neoAg #AACR18
9:32pm April 14th 2018 via Hootsuite
Peters: Finishes with TMB and candidate neoantigen burden. Figu from '15 Science https://t.co/AlDHrqkMEY #AACR18
9:29pm April 14th 2018 via Hootsuite
Peters: "Data across testing platforms must be harmonized" to correlated targeted panels to TMB from WES #AACR18
9:28pm April 14th 2018 via Hootsuite
Peters: concl: targeted NGS a reasonable proxy, but not designed/optimized for this purpose. Genes more likely to be mutated #AACR18
9:27pm April 14th 2018 via Hootsuite
Peters: Also localization affects how much ctDNA available to look at. #AACR18
Peters: Shows nice correlation plot NEJM https://t.co/BaJAoDZW0j TMB and ctDNA: not well correlated b/c: tumors shed differently #AACR18
9:26pm April 14th 2018 via Hootsuite
Peters: CheckMate -227: will be presented here at #AACR18 (Monday). 10 mut /MB by FMI improves OS
9:24pm April 14th 2018 via Hootsuite
Peters: Applying TMB for chemo - no signal there. Applying TMB for MSK-IMPACT: sees that it works (400 genes) #AACR18
9:23pm April 14th 2018 via Hootsuite
